Cargando…
Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines
BACKGROUND: Thoracic tumor, especially lung cancer, ranks as the top cancer mortality in most parts of the world. Lung adenocarcinoma is the predominant subtype and there is increasing knowledge on therapeutic molecular targets, namely EGFR, ALK, KRAS, and ROS1, among lung cancers. Lung cancer cell...
Autores principales: | Lam, David CL, Luo, Susan Y, Deng, Wen, Kwan, Johnny SH, Rodriguez-Canales, Jaime, Cheung, Annie LM, Cheng, Grace HW, Lin, Chi-Ho, Wistuba, Ignacio I, Sham, Pak C, Wan, Thomas SK, Tsao, Sai-Wah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303463/ https://www.ncbi.nlm.nih.gov/pubmed/25653542 http://dx.doi.org/10.2147/OTT.S71242 |
Ejemplares similares
-
Extremely stringent activation of p16(INK4a) prevents immortalization of uterine cervical epithelial cells without human papillomavirus oncogene expression
por: Hang, Su, et al.
Publicado: (2016) -
Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
por: Xu, Wen Wen, et al.
Publicado: (2014) -
A Simple Bias Correction in Linear Regression for Quantitative Trait Association Under Two-Tail Extreme Selection
por: Kwan, Johnny S. H., et al.
Publicado: (2011) -
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
por: Ivanova, Alla V, et al.
Publicado: (2009) -
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non‐small cell lung cancer
por: Shi, Bin, et al.
Publicado: (2019)